Eisai Innovation

Yoshiharu Mizui, the President who founded the unit in 2019, leads the investment team. He is supported by Managing Director Kou Qin in Cambridge and Investment Principal Paul Wu in San Francisco. The website lists these three as the investment leadership, and all have deep scientific backgrounds — Mizui and Qin hold PhDs — rather than purely financial profiles.

It is a wholly owned corporate venture capital arm of Eisai Co., Ltd. The unit invests the parent company's balance sheet directly, not capital from external limited partners. Its stated purpose is to add cutting-edge technologies, drug modalities, and digital healthcare solutions into the Eisai network.

The firm states it typically invests roughly $5 million per transaction. Its investment horizon is approximately ten years to exit, a horizon that reflects the clinical-timeline patience of a pharmaceutical parent rather than a venture fund's ten-year partnership cycle.

Neurology and oncology are the two core disease-area mandates, mirroring the parent company's commercial strengths. The firm also invests in digital health solutions, diagnostics, and novel drug modalities that can complement those therapeutic focuses.

No. Its website lists a global remit that spans the United States, Europe, Japan, China, and emerging markets including Africa. The investment team currently operates from offices in Cambridge, Massachusetts and San Francisco, California.

Eisai Innovation is a subsidiary investment entity formed by Eisai Co., Ltd., the publicly listed Japanese pharmaceutical company with roughly 10,000 employees worldwide. The parent company maintains regional operating units including Eisai Inc. in the United States and Eisai Europe Ltd., and the innovation arm is designed to feed acquired assets into that global commercial infrastructure.

Yes. Its website explicitly invites contact from external parties and instructs them to specify whether the outreach concerns collaborations, investments, or general information. This open-door posture aligns with its stated goal of supporting academic-established startups.